期刊文献+

Current developments in pharmacological therapeutics for chronic constipation 被引量:24

Current developments in pharmacological therapeutics for chronic constipation
原文传递
导出
摘要 Chronic constipation is a common gastrointestinal disease severely affecting the patient's quality of life. The traditional treatment of constipation is the use of laxatives. Recently, several new drugs including lubiprostone, linaclotide and prucalopride have been approved for treatment of chronic constipation. However, a significant unmet medical need still remains, particularly among those patients achieving poor results by current therapies. The 5-EF1'1 receptor modulators velusetrag and naronapride, the guanylate cy-clase C agonist plecanatide and die deal bile acid transporter inhibitor elobixibat are recognized as the most promising drugs under investigation. Herein, we give a comprehensive review on the pharmacological therapeutics for the treatment of chronic constipation, with the purpose of reflecting the drug development trends in this field. (C) 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.orgicenses/by-ne-rid/4.0/). Chronic constipation is a common gastrointestinal disease severely affecting the patient's quality of life. The traditional treatment of constipation is the use of laxatives. Recently, several new drugs including lubiprostone, linaclotide and prucalopride have been approved for treatment of chronic constipation. However, a significant unmet medical need still remains, particularly among those patients achieving poor results by current therapies. The 5-HT4 receptor modulators velusetrag and naronapride,the guanylate cyclase C agonist plecanatide and the ileal bile acid transporter inhibitor elobixibat are recognized as the most promising drugs under investigation. Herein, we give a comprehensive review on the pharmacological therapeutics for the treatment of chronic constipation, with the purpose of reflecting the drug development trends in this field.
出处 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2015年第4期300-309,共10页 药学学报(英文版)
基金 supported by the National Natural Science Foundation of China (No. 81072519) the "111 Project" from the Ministry of Education of China
关键词 Chronic constipation Prokinetic agent 5-HT1 receptor Prosecretory agent Chronic constipation Prokinetic agent 5-HT4 receptor Prosecretory agent
  • 相关文献

参考文献3

二级参考文献34

  • 1[1]Heimpel H.Congenital dyserythropoietic anemias:epidemiology,clinical significance,and progress in understanding their pathogenesis.Ann Hematol 2004; 83:613-621
  • 2[2]Cazzola M,Barosi G,Bergamaschi G,Dezza L,Palestra P,Polino G,Ramella S,Spriano P,Ascari E.Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias.Br J Haematol 1983; 54:649-654
  • 3[3]Iolascon A,D'Agostaro G,Perrotta S,Izzo P,Tavano R,Miraglia del Giudice B.Congenital dyserythropoietic anemia type Ⅱ:molecular basis and clinical aspects.Haematologica 1996; 81:543-559
  • 4[4]Heimpel H,Anselstetter V,Chrobak L,Denecke J,Einsiedler B,Gallmeier K,Griesshammer A,Marquardt T,Janka-Schaub G,Kron M,Kohne E.Congenital dyserythropoietic anemia typeⅡ:epidemiology,clinical appearance,and prognosis based on long-term observation.Blood 2003; 102:4576-4581
  • 5[5]Greiner TC,Burns CP,Dick FR,Henry KM,Mahmood I.Congenital dyserythropoietic anemia type Ⅱ diagnosed in a69-year-old patient with iron overload.Am J Clin Pathol 1992;98:522-525
  • 6[6]Bonkovsky HL,Rubin RB,Cable EE,Davidoff A,Rijcken TH,Stark DD.Hepatic iron concentration:noninvasive estimation by means of MR imaging techniques.Radiology 1999; 212:227-234
  • 7[7]Hovinga JA,Solenthaler M,Dufour JF.Congenital dyserythropoietic anaemia type Ⅱ (HEMPAS) and haemochromatosis:a report of two cases.Eur J Gastroenterol Hepatol 2003; 15:1141-1147
  • 8[8]Wickramasinghe SN.Congenital dyserythropoietic anaemias:clinical features,haematological morphology and new biochemical data.Blood Rev 1998; 12:178-200
  • 9[9]Van Steenbergen W,Matthijs G,Roskams T,Fevery J.Noniatrogenic haemochromatosis in congenital dyserythropoietic anaemia type Ⅱ is not related to C282Y and H63D mutations in the HFE gene:report on two brothers.Acta Clin Belg 2002; 57:79-84
  • 10[10]Bacon BR,Powell LW,Adams PC,Kresina TF,Hoofnagle JH.Molecular medicine and hemochromatosis:at the crossroads.Gastroenterology 1999; 116:193-207

共引文献65

同被引文献142

引证文献24

二级引证文献160

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部